{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:40:10Z","timestamp":1792708810916,"version":"4.5.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science (JSPS) KAKENHI","doi-asserted-by":"publisher","award":["19K07953"],"award-info":[{"award-number":["19K07953"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science (JSPS) KAKENHI","doi-asserted-by":"publisher","award":["17H04192"],"award-info":[{"award-number":["17H04192"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare of Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The spectrum of MOG-IgG-associated disease (MOGAD) includes optic neuritis (ON), myelitis (MY), acute disseminated encephalomyelitis (ADEM), brainstem encephalitis, cerebral cortical encephalitis (CE) and AQP4-IgG-negative neuromyelitis optica spectrum disorder (NMOSD). In MOGAD, MOG-IgG are usually detected in sera (MOG-IgGSERUM), but there have been some seronegative MOGAD cases with MOG-IgG in CSF (MOG-IgGCSF), and its diagnostic implications remains unclear.<\/jats:p>\n                  <jats:p>In this cross-sectional study, we identified patients with paired serum and CSF sent from all over Japan for testing MOG-IgG. Two investigators blinded to MOG-IgG status classified them into suspected MOGAD (ADEM, CE, NMOSD, ON, MY and Others) or not based on the current recommendations. The MOG-IgGSERUM and MOG-IgGCSF titres were assessed with serial 2-fold dilutions to determine end point titres [\u22651:128 in serum and \u22651:1 (no dilution) in CSF were considered positive]. We analysed the relationship between MOG-IgGSERUM, MOG-IgGCSF and the phenotypes with multivariable regression.<\/jats:p>\n                  <jats:p>A total of 671 patients were tested [405 with suspected MOGAD, 99 with multiple sclerosis, 48 with AQP4-IgG-positive NMOSD and 119 with other neurological diseases (OND)] before treatment. In suspected MOGAD, 133 patients (33%) tested MOG-IgG-positive in serum and\/or CSF; 94 (23%) double-positive (ADEM 36, CE 15, MY 8, NMOSD 9, ON 15 and Others 11); 17 (4.2%) serum-restricted-positive (ADEM 2, CE 0, MY 3, NMOSD 3, ON 5 and Others 4); and 22 (5.4%) CSF-restricted-positive (ADEM 3, CE 4, MY 6, NMOSD 2, ON 0 and Others 7). None of AQP4-IgG-positive NMOSD, multiple sclerosis or OND cases tested positive for MOG-IgGSERUM, but two with multiple sclerosis cases were MOG-IgGCSF-positive; the specificities of MOG-IgGSERUM and MOG-IgGCSF in suspected MOGAD were 100% [95% confidence interval (CI) 99\u2013100%] and 99% (95% CI 97\u2013100%), respectively. Unlike AQP4-IgG-positive NMOSD, the correlation between MOG-IgGSERUM and MOG-IgGCSF titres in MOGAD was weak. Multivariable regression analyses revealed MOG-IgGSERUM was associated with ON and ADEM, whereas MOG-IgGCSF was associated with ADEM and CE. The number needed to test for MOG-IgGCSF to diagnose one additional MOGAD case was 13.3 (14.3 for ADEM, 2 for CE, 19.5 for NMOSD, infinite for ON, 18.5 for MY and 6.1 for Others).<\/jats:p>\n                  <jats:p>In terms of MOG-IgGSERUM\/CSF status, most cases were double-positive while including either serum-restricted (13%) or CSF-restricted (17%) cases. These statuses were independently associated with clinical phenotypes, especially in those with ON in serum and CE in CSF, suggesting pathophysiologic implications and the utility of preferential diagnostic testing. Further studies are warranted to deduce the clinical and pathological significance of compartmentalized MOG-IgG.<\/jats:p>","DOI":"10.1093\/brain\/awad122","type":"journal-article","created":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T02:59:38Z","timestamp":1681613978000},"page":"3938-3948","source":"Crossref","is-referenced-by-count":72,"title":["Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids"],"prefix":"10.1093","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0163-8105","authenticated-orcid":false,"given":"Yuki","family":"Matsumoto","sequence":"first","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine , Sendai 980-8574 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiko","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine , Sendai 980-8574 , Japan"},{"name":"Department of Neurology, Tohoku University Hospital , Sendai 980-8574 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Hospital Organization Yonezawa National Hospital , Yonezawa 992-1202 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Takai","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine , Sendai 980-8574 , Japan"},{"name":"Department of Neurology, Tohoku University Hospital , Sendai 980-8574 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Namatame","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine , Sendai 980-8574 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine , Sendai 980-8574 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Misu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine , Sendai 980-8574 , Japan"},{"name":"Department of Neurology, Tohoku University Hospital , Sendai 980-8574 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Fujihara","sequence":"additional","affiliation":[{"name":"Department of Multiple Sclerosis Therapeutics, Fukushima Medical University , Fukushima 960-1295 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Aoki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine , Sendai 980-8574 , Japan"},{"name":"Department of Neurology, Tohoku University Hospital , Sendai 980-8574 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,15]]},"reference":[{"key":"2023090117345211300_awad122-B1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O\u2019Connor","year":"2007","journal-title":"Nat Med"},{"key":"2023090117345211300_awad122-B2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG Encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J Neuroinflammation"},{"key":"2023090117345211300_awad122-B3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"2023090117345211300_awad122-B4","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol"},{"key":"2023090117345211300_awad122-B5","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","article-title":"Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study","volume":"19","author":"Armangue","year":"2020","journal-title":"Lancet Neurol"},{"key":"2023090117345211300_awad122-B6","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"2023090117345211300_awad122-B7","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"2023090117345211300_awad122-B8","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1212\/NXI.0000000000000322","article-title":"MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy","volume":"4","author":"Ogawa","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2023090117345211300_awad122-B9","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/jnnp-2016-315094","article-title":"Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies","volume":"88","author":"Fujimori","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023090117345211300_awad122-B10","doi-asserted-by":"crossref","first-page":"e1351","DOI":"10.1212\/WNL.0000000000012599","article-title":"CNS demyelinating attacks requiring ventilatory support with myelin oligodendrocyte glycoprotein or aquaporin-4 antibodies","volume":"97","author":"Zhao-Fleming","year":"2021","journal-title":"Neurology"},{"key":"2023090117345211300_awad122-B11","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1007\/s00415-019-09440-8","article-title":"Unilateral cortical FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome","volume":"266","author":"Budhram","year":"2019","journal-title":"J Neurol"},{"key":"2023090117345211300_awad122-B12","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/brain\/awaa102","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study","volume":"143","author":"Takai","year":"2020","journal-title":"Brain"},{"key":"2023090117345211300_awad122-B13","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jamaneurol.2021.0912","article-title":"Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing","volume":"78","author":"Sechi","year":"2021","journal-title":"JAMA Neurol."},{"key":"2023090117345211300_awad122-B14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamaneurol.2019.3656","article-title":"Coexistence of myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies in adult and pediatric patients","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol"},{"key":"2023090117345211300_awad122-B15","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"H\u00f6ftberger","year":"2020","journal-title":"Acta Neuropathol"},{"key":"2023090117345211300_awad122-B16","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1212\/NXI.0000000000000089","article-title":"MOG cell-based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2023090117345211300_awad122-B17","doi-asserted-by":"crossref","first-page":"e1250","DOI":"10.1212\/WNL.0000000000007096","article-title":"A multicenter comparison of MOG-IgG cell-based assays","volume":"92","author":"Waters","year":"2019","journal-title":"Neurology"},{"key":"2023090117345211300_awad122-B18","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.1212\/NXI.0000000000000674","article-title":"International multicenter examination of MOG antibody assays","volume":"7","author":"Reindl","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2023090117345211300_awad122-B19","doi-asserted-by":"crossref","first-page":"947630","DOI":"10.3389\/fneur.2022.947630","article-title":"Positive predictive value of MOG-IgG for clinically defined MOG-AD within a real-world cohort","volume":"13","author":"Manzano","year":"2022","journal-title":"Front Neurol"},{"key":"2023090117345211300_awad122-B20","doi-asserted-by":"crossref","first-page":"103746","DOI":"10.1016\/j.msard.2022.103746","article-title":"Implications of low-titer MOG antibodies","volume":"59","author":"Levy","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"2023090117345211300_awad122-B21","doi-asserted-by":"crossref","first-page":"e1867","DOI":"10.1212\/WNL.0000000000008479","article-title":"Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases","volume":"93","author":"Mariotto","year":"2019","journal-title":"Neurology"},{"key":"2023090117345211300_awad122-B22","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1212\/WNL.0000000000012175","article-title":"Difference in the source of anti-AQP4-IgG and anti-MOG-IgG antibodies in CSF in patients with neuromyelitis optica spectrum disorder","volume":"97","author":"Akaishi","year":"2021","journal-title":"Neurology"},{"key":"2023090117345211300_awad122-B23","doi-asserted-by":"crossref","first-page":"e1095","DOI":"10.1212\/NXI.0000000000001095","article-title":"Myelin oligodendrocyte glycoprotein-immunoglobulin G in the CSF: clinical implication of testing and association with disability","volume":"9","author":"Kwon","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2023090117345211300_awad122-B24","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00401-021-02286-3","article-title":"Antibodies to MOG in CSF only: pathological findings support the diagnostic value","volume":"141","author":"Carta","year":"2021","journal-title":"Acta Neuropathol"},{"key":"2023090117345211300_awad122-B25","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.msard.2018.12.035","article-title":"Clinical significance of assaying anti-MOG antibody in cerebrospinal fluid in MOG-antibody-associated diseases: a case report","volume":"28","author":"Aoe","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"2023090117345211300_awad122-B26","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/jnnp-2021-326779","article-title":"Frequency of MOG-IgG in cerebrospinal fluid versus serum","volume":"93","author":"Pace","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023090117345211300_awad122-B27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jns.2018.06.028","article-title":"The pathological features of MOG antibody-positive cerebral cortical encephalitis as a new spectrum associated with MOG antibodies: a case report","volume":"392","author":"Ikeda","year":"2018","journal-title":"J Neurol Sci"},{"key":"2023090117345211300_awad122-B28","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/ene.13790","article-title":"Encephalitis is an important clinical component of myelin oligodendrocyte glycoprotein antibody associated demyelination: a single-center cohort study in Shanghai, China","volume":"26","author":"Wang","year":"2019","journal-title":"Eur J Neurol"},{"key":"2023090117345211300_awad122-B29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"2023090117345211300_awad122-B30","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International pediatric multiple sclerosis study group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Multiple Sclerosis Journal"},{"key":"2023090117345211300_awad122-B31","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","article-title":"Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre","volume":"130","author":"Takahashi","year":"2007","journal-title":"Brain"},{"key":"2023090117345211300_awad122-B32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"2023090117345211300_awad122-B33","doi-asserted-by":"crossref","first-page":"e1095","DOI":"10.1212\/WNL.0000000000201662","article-title":"Significance of myelin oligodendrocyte glycoprotein antibodies in CSF: a retrospective multicenter study","volume":"100","author":"Carta","year":"2022","journal-title":"Neurology"},{"key":"2023090117345211300_awad122-B34","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1212\/NXI.0000000000000231","article-title":"Clinical utility of testing AQP4-IgG in CSF: guidance for physicians","volume":"3","author":"Majed","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2023090117345211300_awad122-B35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"Igg marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"2023090117345211300_awad122-B36","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1620\/tjem.209.269","article-title":"Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: a case report","volume":"209","author":"Misu","year":"2006","journal-title":"Tohoku J Exp Med"},{"key":"2023090117345211300_awad122-B37","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1093\/brain\/awab102","article-title":"Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders","volume":"144","author":"Takai","year":"2021","journal-title":"Brain"},{"key":"2023090117345211300_awad122-B38","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic\u2019s neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"key":"2023090117345211300_awad122-B39","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023090117345211300_awad122-B40","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1212\/WNL.0b013e3181a82621","article-title":"A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset","volume":"72","author":"Nishiyama","year":"2009","journal-title":"Neurology"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awad122\/50522585\/awad122.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/146\/9\/3938\/51330675\/awad122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/146\/9\/3938\/51330675\/awad122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T14:05:13Z","timestamp":1702217113000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/146\/9\/3938\/7123636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,15]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,4,15]]},"published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awad122","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,4,15]]}}}